Nicox S.A. Logo

Nicox S.A.

COX | PA

Overview

Corporate Details

ISIN(s):
FR0013018124 (+6 more)
LEI:
969500EZGEO9W4JXR353
Country:
France
Address:
SOPHIA, 06410 BIOT
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Developing innovative ocular solutions Nicox is an international ophthalmology company developing innovative therapeutics to help maintain vision and improve ocular health. We plan to keep the maximum of options open for the company by maintaining rights to our novel therapeutics for eye diseases in key territories, such as the U.S. and Europe, as we create value by advancing their development, maintaining the potential for direct marketing, licensing for certain territories and growth through strategic transactions. We are focused on the discovery, development and commercialization of novel ophthalmic therapeutics for eye diseases.

Social Media

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-12 15:53
Major Shareholding Notification
Franchissement de seuils
French 113.6 KB
2025-08-08 07:30
Capital/Financing Update
Nicox Extends Existing Flexible Equity Financing
English 181.9 KB
2025-08-05 07:30
Regulatory News Service
Nicox annonce l’initiation par son partenaire Kowa d’un essai clinique de Phase…
French 176.0 KB
2025-08-05 07:30
Regulatory News Service
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
English 171.5 KB
2025-06-30 07:30
Regulatory News Service
Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Dena…
French 161.2 KB
2025-06-30 07:30
Regulatory News Service
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
English 156.1 KB
2025-06-06 07:30
Pre-Annual General Meeting Information
Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 27 ju…
French 184.6 KB
2025-06-06 07:30
Pre-Annual General Meeting Information
Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 2…
English 175.2 KB
2025-05-27 07:30
Regulatory News Service
Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX…
English 179.6 KB
2025-05-27 07:30
Regulatory News Service
Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Ko…
French 183.6 KB
2025-05-14 07:30
Earnings Release
Nicox annonce les résultats de l’étude exploratoire de phase 3b Whistler dans l…
French 199.5 KB
2025-05-14 07:30
Earnings Release
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
English 184.4 KB
2025-04-30 07:30
Earnings Release
Nicox Provides Full Year 2024 Financial Results
English 181.9 KB
2025-04-30 07:30
Earnings Release
Nicox : Résultats financiers de l’année 2024
French 180.4 KB
2025-03-19 07:30
Regulatory News Service
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler…
English 218.6 KB

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies